Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL

• Hoofdauteurs: Annamaria Mascolo (Auteur), Raffaella Di Napoli (Auteur), Nunzia Balzano (Auteur), Elena D'Alessio (Auteur), Imma Izzo (Auteur), Francesco Rossi (Auteur), Giuseppe Paolisso (Auteur), Annalisa Capuano (Auteur), Liberata Sportiello (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2023-08-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Introduction: Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is authorized for the treatment of chronic lymphocytic leukemia (CLL). This study aims to explore the cardiac safety profile of ibrutinib in comparison with obinutuzumab.Methods: A retrospective pharmacovigilance study was con...